Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lantheus Biosciences Ltd.
Age
18–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males/females \>/= 18 years
Patients with a diagnosis of primary prostate cancer (biopsy proven) and scheduled for radical prostatectomy or patients with prostate tumor recurrence (Patients with advanced tumor disease and a high likelihood to display lymph node metastasis are to be preferably included.)
ECOG (Eastern Cooperative Oncology Group) performance status of 0-2, determined within one week prior to treatment with BAY94-9392
Patient had an \[18F\]-fluorodeoxyglucose (FDG) PET/CT for detection, or staging, or restaging, or therapy response assessment that still showed tumor mass with high certainty for a cancer such as melanoma, or colorectal cancer, or head \& neck cancer for which FDG-PET/CT is used in clinical routine, and the primary cancer disease is histologically confirmed. In case of recurrent disease confirmation of the primary tumor is sufficient
No clinically relevant deviations in renal function as determined by Cockcroft and Gault method using serum creatinine at screening.
You may not be if
Concurrent severe and/or uncontrolled and/or unstable medical disease other than cancer or inflammation (e.g. poorly controlled diabetes, congestive heart failure, myocardial infarction within 12 months prior to planned injection of BAY94-9392, unstable and uncontrolled hypertension, chronic renal or hepatic disease, severe pulmonary disease) which could compromise participation in the study
Known sensitivity to the study drug or components of the preparation
Previous treatment with BAY94-9392 in this study
Clareo Health | Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer
